The Assisted Reproductive Technology Drugs Treatment segmentation by type disaggregates the market into gonadotropins, GnRH analogues, estrogen antagonists, progesterone, human chorionic gonadotropin, and others. Gonadotropins—comprising recombinant FSH, highly-purified FSH, and urinary-derived menotropins—command the largest revenue share (≈42 % in 2023) because controlled ovarian hyper-stimulation cycles are drug-intensive and repeated across 3-4 treatment attempts. Recombinant versions are preferred for batch-to-batch consistency, but urinary products retain cost-sensitive niches, creating a bimodal price-volume equilibrium that underpins overall market size. GnRH analogues (agonists and antagonists) rank second, valued for their ability to prevent premature LH surges; patent expiry of short antagonist protocols is shifting volume toward lower-priced generics while keeping value growth modest. Estrogen antagonists—primarily clomiphene citrate—remain high-volume, low-value cornerstones of ovulation induction, limiting per-patient revenue yet broadening eligible population estimates. Progesterone, essential for luteal support, is increasingly delivered via vaginal gels that extend prescription duration, adding recurrent revenue. hCG triggers contribute modest value but are indispensable for final oocyte maturation, whereas the residual “others” segment captures adjuvant dopamine agonists and DHEA, reflecting incremental off-label expansion rather than material share.
